Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J. Hengeveld, Anton W. Langerak, Peter E. Westerweel et al.|Blood|2022Cited by 24
Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosisP. Martijn Kolijn, Anton W. Langerak, Florentin Späth et al.|Blood|2023Cited by 7
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLLPaul J. Hengeveld, Anton W. Langerak, P. Martijn Kolijn et al.|HemaSphere|2023Cited by 5
High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic LeukemiaPaul J. Hengeveld, Mark‐David Levin, P. Martijn Kolijn et al.|Blood|2022Cited by 0
P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSISP. Martijn Kolijn, Anton W. Langerak, Florentin Späth et al.|HemaSphere|2023Cited by 0